Citations

Clear

6273 citation(s) found for "To, Andrew".

Introduction. Machine learning in neurosurgery: transitioning to a new era of contemporary medicine
Bydon, Mohamad , Timmons, Shelly D. , Potts, Eric A. , Chan, Andrew K. , Shin, John H.

Mayo Clinic

Neurosurgical Focus | June 1, 2023 | Volume: 54 | Issue: 6 | Pages: E1

10.3171/2023.3.focus23210 | PMID 37283441 Get It

Authors' Reply: Urine Metabolomic Versus Standard Chemistry Analysis: What can Metabolomic Analysis Bring to the Treatment and Prevention of Urolithiasis?
Thongprayoon, Charat , Lieske, John C. , Rule, Andrew D., Đenić, Aleksandar , Denic, Aleksandar , Lieske, John C , Thongprayoon, Charat , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | June 1, 2023 | Volume: 34 | Issue: 6 | Pages: 1124-1125

10.1681/asn.0000000000000138 | PMID 37259199 Get It

Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study
Raynaud, Marc , Awadhi, Solaf Al, Divard, Gillian , Dubourg, Laurence , Mariat, Christophe , Prié, Dominique , Pernin, Vincent , Larson, Timothy S., Bikbov, Boris , Ruggenenti, Piero , Ibrahim, Hassan N. , Nielsen, Marie Bodilsen , Matas, Arthur J. , Nankivell, Brian J. , Benjamens, Stan , Pol, Robert A. , Bakker, Stephan J. L. , Jouven, Xavier , Legendre, Christophe , Wadei, Hani M. , Dürrbach, Antoine , Vincenti, Flavio , Lefaucheur, Carmen , Loupy, Alexandre , Wadei, Hani M , Al-Awadhi, Solaf , Divard, Gillian , Jurić, Ivana , Lombardi, Yannis , Bašić‐Jukić, Nikolina , Aubert, Olivier , Masson, Ingrid , Quintrec, Moglie Le , Stegall, Mark D. , Mesnard, Laurent , Kamar, Nassim , Smith, Byron H. , Remuzzi, Giuseppe , Bentall, Andrew , Loupy, Alexandre

Mayo Clinic

BMJ | May 31, 2023 | Volume: 381 | Issue: No issue available | Pages: e073654

10.1136/bmj-2022-073654 | PMID 37257905 Get It

Abstract Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with the three current main equations for measuring GFR in kidney transplant recipients. Design Development and validation study Setting 17 cohorts in Europe, the United States, and Australia (14 transplant centres, three clinical trials). Participants 15 489 adults (3622 in development cohort (Necker, Saint Louis, and Toulouse hospitals, France), 11 867 in multiple external validation cohorts) who received kidney transplants between 1 January 2000 and 1 January 2021. Main outcome measure The main outcome measure was GFR, measured according to local practice. Performance of the GFR equations was assessed using P 30 (proportion of estimated GFR (eGFR) within 30% of measured GFR (mGFR)) and correct classification (agreement between eGFR and mGFR according to GFR stages). The race-free equation, based on creatinine level, age, and sex, was developed using additive and multiplicative linear regressions, and its performance was compared with the three current main GFR equations: Modification of Diet in Renal Disease (MDRD) equation, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation, and race-free CKD-EPI 2021 equation. Results The study included 15 489 participants, with 50 464 mGFR and eGFR values. The mean GFR was 53.18 mL/min/1.73m 2 (SD 17.23) in the development cohort and 55.90 mL/min/1.73m 2 (19.69) in the external validation cohorts. Among the current GFR equations, the race-free CKD-EPI 2021 equation showed the lowest performance compared with the MDRD and CKD-EPI 2009 equations. When race was included in the kidney recipient specific GFR equation, performance did not increase. The race-free kidney recipient specific GFR equation showed significantly improved performance compared with the race-free CKD-EPI 2021 equation and performed well in the external validation cohorts (P 30 ranging from 73.0% to 91.3%). The race-free kidney recipient specific GFR equation performed well in several subpopulations of kidney transplant recipients stratified by race (P 30 73.0-91.3%), sex (72.7-91.4%), age (70.3-92.0%), body mass index (64.5-100%), donor type (58.5-92.9%), donor age (68.3-94.3%), treatment (78.5-85.2%), creatinine level (72.8-91.3%), GFR measurement method (73.0-91.3%), and timing of GFR measurement post-transplant (72.9-95.5%). An online application was developed that estimates GFR based on recipient’s creatinine level, age, and sex ( https://transplant-prediction-system.shinyapps.io/eGFR_equation_KTX/ ). Conclusion A new race-free kidney recipient specific GFR equation was developed and validated using multiple, large, international cohorts of kidney transplant recipients. The equation showed high accuracy and outperformed the race-free CKD-EPI 2021 equation that was developed in individuals with native kidneys. Trial registration ClinicalTrials.gov NCT05229939 .
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis
Waters, Margo , Dobry, Allison S. , Le, Stephanie T. , Shinkai, Kanade , Beachkofsky, Thomas M. , Davis, Mark D.P. , Markova, Alina , Pasieka, Helena B. , Rosenbach, Misha , Seminario‐Vidal, Lucia , Trinidad, John , Altman, Emily , Arakaki, Ryan, Ardern‐Jones, Michael R. , Bridges, Alina G. , Cardones, Adela R. , Chen, Jennifer K. , Chen, Steven T. , Cheng, Kyle , Harp, Joanna, King, Brett , Lowenstein, Eve J. , Luxenberg, Erin, Mancuso, Jennifer , Mauskar, Melissa , Milam, Philip , Nelson, Caroline A. , Nguyen, Cuong V. , Nutan, Fnu, Patel, Tejesh , Rahnama‐Moghadam, Sahand , Rekhtman, Sergey , Rojek, Nathan W. , Sarihan, Mansi, Shaigany, Sheila , Sharma, Timmie R. , Shearer, Sabrina M, Shields, Bridget E. , Strowd, Lindsay C. , Tartar, Danielle , Walls, Andrew C., Ziemer, Carolyn, Kaffenberger, Benjamin H. , Nguyen, C V , Seminario-Vidal, L , Kaffenberger, B , Dominguez, Arturo Ricardo , Kroshinsky, Daniela , Micheletti, Robert , Mostaghimi, Arash , Albrecht, Joerg , Chadha, Angad , Daveluy, Steven , DeNiro, Katherine L. , Keller, Jesse Joel , Korman, Abraham Moris , Motaparthi, Kiran , Ortega‐Loayza, Alex G. , Shaigany, Sheila , Thomas, Cristina , Wanat, Karolyn A. , Walls, Andrew F. , Zaba, Lisa C. , Maverakis, Emanual Michael

Mayo Clinic

JAMA Dermatology | May 31, 2023 | Volume: 159 | Issue: 7 | Pages: 772

10.1001/jamadermatol.2023.1347 | PMID 37256599 Get It

Importance Scoring systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosis and are weighted toward comorbidities and systemic features; morphologic terminology for EN lesions is inconsistent. Objectives To establish consensus among expert dermatologists on EN terminology, morphologic progression, and most-affected sites, and to build a framework for developing a skin-directed scoring system for EN. Evidence Review A Delphi consensus using the RAND/UCLA appropriateness criteria was initiated with a core group from the Society of Dermatology Hospitalists to establish agreement on the optimal design for an EN cutaneous scoring instrument, terminology, morphologic traits, and sites of involvement. Findings In round 1, the 54 participating dermatology hospitalists reached consensus on all 49 statements (30 appropriate, 3 inappropriate, 16 uncertain). In round 2, they agreed on another 15 statements (8 appropriate, 7 uncertain). There was consistent agreement on the need for a skin-specific instrument; on the most-often affected skin sites (head and neck, chest, upper back, ocular mucosa, oral mucosa); and that blanching erythema, dusky erythema, targetoid erythema, vesicles/bullae, desquamation, and erosions comprise the morphologic traits of EN and can be consistently differentiated. Conclusions and Relevance This consensus exercise confirmed the need for an EN skin-directed scoring system, nomenclature, and differentiation of specific morphologic traits, and identified the sites most affected. It also established a baseline consensus for a standardized EN instrument with consistent terminology.
Age-Based Versus Young-Adult Thresholds for Nephrosclerosis on Kidney Biopsy and Prognostic Implications for CKD
Asghar, Muhammad Sohaib , Đenić, Aleksandar , Mullan, Aidan F. , Moustafa, Amr A. , Barisoni, Laura , Alexander, Mariam P., Augustine, Joshua J. , Leibovich, Bradley C. , Thompson, R. Houston, Alexander, Mariam P. , Asghar, Muhammad S , Moustafa, Amr , Alexander, Mariam P , Leibovich, Bradley C , Rule, Andrew D , Denic, Aleksandar , Barisoni, Laura , Mullan, Aidan , Stegall, Mark D. , Augustine, Joshua , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | May 31, 2023 | Volume: 34 | Issue: 8 | Pages: 1421-1432

10.1681/asn.0000000000000171 | PMID 37254246 Get It

Significance Statement Nephrosclerosis (glomerulosclerosis, interstitial fibrosis, and tubular atrophy) is the defining pathology of both kidney aging and CKD. Optimal thresholds for nephrosclerosis that identify persons with a progressive disease are unknown. This study determined a young-age threshold (18–29 years) and age-based 95th percentile thresholds for nephrosclerosis on the basis of morphometry of kidney biopsy sections from normotensive living kidney donors. These thresholds were 7.1-fold to 36-fold higher in older (70 years or older) versus younger (aged 18–29 years) normotensive donors. Age-based thresholds, but not young-age threshold, were prognostic for determining risk of progressive CKD among patients who underwent a radical nephrectomy or a for-cause native kidney biopsy, suggesting that age-based thresholds are more useful than a single young-age threshold for identifying CKD on biopsy. Background Nephrosclerosis, defined by globally sclerotic glomeruli (GSG) and interstitial fibrosis and tubular atrophy (IFTA), is a pathology of both kidney aging and CKD. A comparison of risk of progressive CKD using aged-based thresholds for nephrosclerosis versus a single young-adult threshold is needed. Methods We conducted morphometric analyses of kidney biopsy images for %GSG, %IFTA, and IFTA foci density among 3020 living kidney donors, 1363 patients with kidney tumor, and 314 patients with native kidney disease. Using normotensive donors, we defined young-age thresholds (18–29 years) and age-based (roughly by decade) 95th percentile thresholds. We compared age-adjusted risk of progressive CKD (kidney failure or 40% decline in eGFR) between nephrosclerosis that was “normal compared with young,” “normal for age but abnormal compared with young,” and “abnormal for age” in patients with tumor and patients with kidney disease. Results The 95th percentiles in the youngest group (18–29 years) to the oldest group (70 years or older) ranged from 1.7% to 16% for %GSG, 0.18% to 6.5% for %IFTA, and 8.2 to 59.3 per cm 2 for IFTA foci density. Risk of progressive CKD did not differ between persons with nephrosclerosis “normal compared with young” versus “normal for age but abnormal compared with young.” Risk of progressive CKD was significantly higher with %GSG, %IFTA, or IFTA foci density that was abnormal versus normal for age in both cohorts. Conclusions Given that increased risk of progressive CKD occurs only when nephrosclerosis is abnormal for age, age-based thresholds for nephrosclerosis seem to be better than a single young-age threshold for identifying clinically relevant CKD.
Abstract CT013: Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma
Kapoor, Prashant , Pianko, Matthew J. , Magyar, Andrew P., Aina, Oluwaseun, Boyapati, Anita , Cronier, Damien M., Rodriguez-Lorenc, Karen, Kroog, Glenn S. , Suvannasankha, Attaya , Richter, Joshua , D’Souza, Anita , Anderson, Larry D. , Magyar, Andrew, Singh, Nikhil , Lee, Hans C.

Mayo Clinic

Cancer Research | May 30, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT013-CT013

10.1158/1538-7445.am2023-ct013 Get It

Abstract Background: MM remains incurable and new tx options are needed, especially in heavily pre-treated R/R pts. REGN5459, a BCMAxCD3 bispecific Ab, binds to BCMA on MM cells and with low affinity to CD3 on T cells, triggering T-cell activation and plasma cell depletion with low cytokine release preclinically. This first-in-human study aimed to assess the safety, tolerability, and preliminary anti-tumor activity of REGN5459 monotherapy in pts with R/R MM. Methods: Eligible pts had received ≥3 prior lines of tx including an anti-CD38 Ab, proteasome inhibitor, and immunomodulatory drug, and had exhausted all available tx options. Pts could receive REGN5459 until progression/intolerable toxicity. Primary objectives were to assess safety, tolerability, dose limiting toxicities (DLTs), and determine the recommended Ph 2 dose (RP2D) of REGN5459 (Ph 1) and assess efficacy of REGN5459 (Ph 2) per ORR. Results: As of June 9, 2022, 43 pts were enrolled (Ph 1, 33; Ph 2, 10): median age 67 yrs (range, 26-85), 51% female, 16% high cytogenetic risk, 14% extramedullary plasmacytoma, 37% R-ISS Stage III disease, 61% triple-class refractory, and median of 5 (range, 2-9) prior lines of tx. In Ph 1, one DLT was reported in a pt receiving the highest dose (900 mg; Gr 3 hypoxia, pt later found to have primary lung cancer). RP2D was identified as 480 mg. All pts enrolled had ≥1 TEAE, 74% had Gr ≥3 TEAEs. TEAEs all-Gr in ≥30% of pts were CRS (54%), fatigue (44%), neutropenia (37%), anemia (35%), cough (30%), and diarrhea (30%). Gr ≥3 TEAEs in ≥15% of pts were neutropenia (37%), anemia (26%), lymphopenia (23%), thrombocytopenia (19%), and hypertension (16%). CRS Gr 1, 2, and 3 were reported in 47%, 2%, and 5%, respectively; there was no Gr 4 or 5 CRS. No Gr 3 CRS with RP2D. Tocilizumab was used in 19% and steroids in 9% of pts. One pt developed ICANS (2%, Gr 2). Incidence of serious TEAEs and TEAEs leading to tx discontinuation was 63% and 16%. Infections occurred in 61% (37% Gr ≥3). After data-cutoff, two deaths due to COVID pneumonia and COVID infection have been reported. ORR was 67% (58% ≥VGPR) for the entire cohort and 100% (85% ≥VGPR; 15% sCR; 39% CR) among pts receiving the RP2D (n=13). Median follow-up was 7 mos (range, 1-26) with longest response ongoing for 22+ mos. Median time to response was 0.8 mos. Median DOR was NR (95% CI, 12-NE); 12-mo DOR for RP2D was 66.7% (95% CI, 5.4-94.5). Of pts in ≥CR with available MRD results (n=8), 50% were MRD negative at the 10−5 threshold. Conclusion: These initial data show that REGN5459 has acceptable safety/tolerability in R/R MM with most CRS of low grade and low incidence of ICANS. Modulation of CD3 affinity on bispecific Abs to maximize tumor killing, and mitigate CRS and T-cell exhaustion, warrants further research. Efficacy in this heavily pre-treated cohort was encouraging, with 100% ORR with the RP2D. Updated data will be presented at the meeting. Citation Format: Attaya Suvannasankha, Prashant Kapoor, Matthew J. Pianko, Joshua Richter, Anita D'Souza, Larry D. Anderson, Andrew Magyar, Oluwaseun Aina, Anita Boyapati, Damien Cronier, Nikhil Singh, Karen Rodriguez-Lorenc, Glenn S. Kroog, Hans C. Lee. Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT013.
Prognostic Significance of Early Declines in Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation
Yadav, Hemang , Torghabeh, Mehrdad Hefazi, Hefazi, Mehrdad , Hogan, William J. , Limper, Andrew H.

Mayo Clinic

Respiratory Care | May 30, 2023 | Volume: 68 | Issue: 10 | Pages: 1406-1416

10.4187/respcare.10925 | PMID 37253610 Get It

BACKGROUND: Pulmonary function test (PFT) impairments are common after allogeneic hematopoietic stem cell transplantation. The prognostic significance of these declines on outcomes is not well understood. The objectives were to determine the frequency of declines in pulmonary function (FVC, FEV 1 , and diffusing capacity for carbon monoxide [D LCO ]) in the early post-transplantation period; and to determine the prognostic significance of these declines on mortality or development of bronchiolitis obliterans syndrome. METHODS: This was a retrospective cohort study conducted at Mayo Clinic, Rochester, Minnesota. PFTs were obtained at baseline and at day +100. Competing risk survival models were developed, which accounted for pre-transplantation pulmonary function and relapse status. RESULTS: Between January 1, 2005, and December 31, 2020, 1,145 subjects underwent allogeneic hematopoietic stem cell transplantation and had a pre-transplantation PFT performed. Of these, 900 (78.6%) survived to day 100 and had post-transplantation PFTs performed (median [interquartile range] 97 [94–103] d). A decline of ≥10% in FEV 1, FVC, or D LCO was seen in 401 of 900 subjects (44.5%). Declines of ≥20% in FEV 1 (hazard ratio 1.65, 95% CI 1.07–2.56; P = .02), FVC (hazard ratio 1.72, 95% CI [1.11–2.67]; P = .02), and D LCO (hazard ratio 1.46, 95% CI 1.04–2.07; P = .028) were all associated with reduced survival when compared with those with < 10% decline in PFT measures. These findings were independent of pre-transplantation pulmonary function or relapse status. Bronchiolitis obliterans syndrome was diagnosed in 118 subjects (10.3%), and there was no relationship between early PFT decline and a subsequent diagnosis of bronchiolitis obliterans syndrome. The subjects who received myeloablative conditioning with cyclophosphamide plus total body irradiation or cyclophosphamide plus fludarabine plus total body irradiation were more likely to have lower spirometry values after hematopoietic stem cell transplantation. The subjects who received reduced intensity conditioning or nonmyeloablative conditioning with fludarabine plus total body irradiation were more likely to have higher post–hematopoietic stem cell transplantation FEV 1 , FVC, and D LCO . CONCLUSIONS: An absolute decline of ≥20% in FEV 1 , FVC, or D LCO were associated with reduced survival independent of pre-transplantation pulmonary function or relapse status. In contrast to previous work, early declines in PFT measures were not associated with future development of bronchiolitis obliterans syndrome.
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk
Aglago, Elom K. , Kim, Andre E. , Lin, Yi , Qu, Conghui , Evangelou, Marina , Yu, Ren , Morrison, John L. , Albanes, Demetrius , Arndt, Volker , Barry, Elizabeth L. , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Díez‐Obrero, Virginia , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jordahl, Kristina M. , Joshi, Amit D. , Kundaje, Anshul , Li, Li , Mandic, Marko , Obón‐Santacana, Mireia , Nan, Hongmei , Nassir, Rami , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Prentice, Ross L. , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Gauderman, W. James , Peters, Ulrike , Kim, Andre E , Ren, Yu , Morrison, John L , Bien, Stephanie A , Bishop, D Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D , Budiarto, Arif , Carreras-Torres, Robert , Casey, Graham , Cenggoro, Tjeng Wawan , Chan, Andrew T , Chang-Claude, Jenny , Chen, Xuechen , Conti, David V , Devall, Matthew A M , Diez-Obrero, Virginia , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Gallinger, Steven , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Hidaka, Akihisa , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Joshi, Amit D , Kawaguchi, Eric , Keku, Temitope O , Kundaje, Anshul , Larsson, Susanna C , Marchand, Loïc Le , Lewinger, Juan Pablo , Li, Li , Lynch, Brigid M , Mahesworo, Bharuno , Mandic, Marko , Obón-Santacana, Mireia , Moreno, Victor , Murphy, Neil , Nan, Hongmei , Nassir, Rami , Newcomb, Polly A. , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Papadimitriou, Nikos , Pardamean, Bens , Peoples, Anita R , Platz, Elizabeth A. , Potter, John D , Prentice, Ross L , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Scacheri, Peter C , Schmit, Stephanie L , Schoen, Robert E , Shcherbina, Anna , Slattery, Martha L , Stern, Mariana Carla , Su, Yu-Ru , Tangen, Catherine M , Thibodeau, Stephen N , Thomas, Duncan C , Tian, Yu , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Vodicka, Pavel , Wang, Jun , White, Emily , Wolk, Alicja , Woods, Michael O , Wu, Anna H. , Zemlianskaia, Natalia , Hsu, Li , Gauderman, W James , Peters, Ulrike , Tsilidis, Konstantinos K , Campbell, Peter T , Arndt, Volker , Aglago, Elom K , Albanes, Demetrius , Qu, Conghui , Bien, Stephanie A. , Buchanan, Daniel D. , Carreras‐Torres, Robert , Chan, Andrew T. , Conti, David V. , Dimou, Niki , Drew, David A. , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Murphy, Neil , Palmer, Julie R. , Pardamean, Bens , Potter, John D. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Shcherbina, Anna , Tangen, Catherine M. , Tian, Yu , Ulrich, Cornelia M. , Wolk, Alicja , Tsilidis, Konstantinos K. , Campbell, Peter T.

Mayo Clinic

Cancer Research | May 30, 2023 | Volume: 83 | Issue: 15 | Pages: 2572-2583

10.1158/0008-5472.can-22-3713 | PMID 37249599 Get It

Abstract Colorectal cancer risk can be impacted by genetic, environmental, and lifestyle factors, including diet and obesity. Gene-environment interactions (G × E) can provide biological insights into the effects of obesity on colorectal cancer risk. Here, we assessed potential genome-wide G × E interactions between body mass index (BMI) and common SNPs for colorectal cancer risk using data from 36,415 colorectal cancer cases and 48,451 controls from three international colorectal cancer consortia (CCFR, CORECT, and GECCO). The G × E tests included the conventional logistic regression using multiplicative terms (one degree of freedom, 1DF test), the two-step EDGE method, and the joint 3DF test, each of which is powerful for detecting G × E interactions under specific conditions. BMI was associated with higher colorectal cancer risk. The two-step approach revealed a statistically significant G×BMI interaction located within the Formin 1/Gremlin 1 (FMN1/GREM1) gene region (rs58349661). This SNP was also identified by the 3DF test, with a suggestive statistical significance in the 1DF test. Among participants with the CC genotype of rs58349661, overweight and obesity categories were associated with higher colorectal cancer risk, whereas null associations were observed across BMI categories in those with the TT genotype. Using data from three large international consortia, this study discovered a locus in the FMN1/GREM1 gene region that interacts with BMI on the association with colorectal cancer risk. Further studies should examine the potential mechanisms through which this locus modifies the etiologic link between obesity and colorectal cancer. Significance: This gene-environment interaction analysis revealed a genetic locus in FMN1/GREM1 that interacts with body mass index in colorectal cancer risk, suggesting potential implications for precision prevention strategies.
Airway luminal area in long COVID patients compared to acute COVID-19 patients
Zaremba, Solomiia , Miller, Alex , Ovrom, Erik A. , Dominelli, Paolo B. , Joyner, Michael J. , Welch, Brian T. , Miller, Alex J. , Joyner, Michael J , Senefeld, Jonathon W. , Wiggins, Chad C. , Ramsook, Andrew H

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731335 Get It

Background: Patients with respiratory manifestations of acute COVID-19 infection have enlarged luminal areas of central conducting airways demonstrated on computed tomography imaging and abnormal pulmonary function. In some cases, COVID-19 symptoms may persist for more than 4 weeks, referred to as long COVID, and the effect on airway luminal area remains unknown. Herein, we report airway luminal cross-sections areas among a long COVID group, compared to individuals with an acute COVID-19. We aim to investigate if large conducting airways sizes are different between acute COVID-19 and long COVID patients. Methods: A cohort of 181 people with long COVID were screened, of which 20 people (9 men, 11 women; 55.9 ± 14.1 years) were included in analyses. Twenty age, height, and sex matched patients with an acute (< 4 weeks of persistent symptoms from diagnosis) COVID-19 infection (55.7 ± 15.2 years) served as a comparison group. We used a three-dimensional reconstruction of computed tomography imaging to measure luminal areas of the trachea, right and left main bronchi, bronchus intermediate, right and left upper lobe, and left lower lobe bronchi at proximal, middle, and distal cross-sectional points in both groups. Airway luminal area was taken as the average of the three points. We compared average lumen area of long COVID patients with acute COVID-19 individuals, using an independent samples t-test. Results: We found no significant difference comparing measurements of the following airway luminal cross-sectional areas: trachea (277.7 ± 100.4 vs. 268.0 ± 70.5 mm2 p=0.73), right main bronchus (191.0 ± 66.1 vs. 190.1 ± 49.0 mm2, p=0.96), bronchus intermediate (112.3 ± 33.4 vs. 109.3 ± 27.9 mm2, p=0.76), right upper lobe bronchus (74.4 ± 21.0 vs. 73.7 ± 25.5 mm2, p=0.92), left main bronchus (129.1 ± 50.1 vs. 136.9 ± 38.0 mm2, p=0.58), left lower lobe bronchus (57.8 ± 18.2 vs. 59.0 ± 13.4 mm2, p=0.82), and left upper lobe bronchus (80.1 ± 19.5 vs. 77.9 ± 22.9 mm2, p=0.75) in the long COVID and acute COVID-19 groups respectively. Conclusion: In patients with long COVID, compared to those with an acute COVID-19 infection, we did not see differences in central airway luminal areas. Further analysis of a larger cohort is needed to determine whether enlarged airway luminal areas, associated with acute COVID-19, persist in long COVID. This research will expand knowledge on functional consequences for patients with long COVID. Funding: F32HL154320 to JWS; 5R35HL139854 to MJJ. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Sex differences in central airway luminal area among people with interstitial lung disease
Miller, Alex, Ovrom, Erik A. , Dominelli, Paolo B. , Joyner, Michael J. , Welch, Brian T. , Miller, Alex J. , Joyner, Michael J , Miller, Alex, Senefeld, Jonathon W. , Wiggins, Chad C. , Ramsook, Andrew H

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731276 Get It

Background: Interstitial lung disease (ILD) encompasses several pulmonary disorders associated with scarring and fibrosis of pulmonary tissue. People with idiopathic pulmonary fibrosis, a subset of ILD, have greater central airway luminal area compared to age- and sex-matched healthy controls when evaluated using microcomputed tomography, a process examining the luminal area of ex-vivo lung tissue. In this study we aimed to confirm these findings using a different method of airway assessment, three-dimensional (3D) reconstruction of computed tomography (CT) scans. Moreover, in health, males have larger central airways than height-matched females, but it remains unknown if there are sex differences in airway area among people with ILD. We hypothesized that sex differences observed in healthy people would persist among people with ILD. Methods: A cohort of 399 patients with lung CT scans were screened, of which 19 people (7 females) with ILD were included in analyses after exclusions. People with ILD were matched based on sex, age, and height to 19 healthy controls. We assessed cross-sectional luminal area at the midpoint of seven conducting airways (trachea, left and right main bronchus, intermediate bronchus, left and right upper lobe, and left lower lobe). Results from pulmonary function tests were also abstracted, as available. To examine sex differences, we compared airway luminal area, normalized to participant height, between males and females with ILD. Sex differences were analyzed using a univariate ANOVA test. Results: People with ILD had a preserved ratio of forced expiratory volume in the first second to forced vital capacity (101 ±12%predicted) and decreased diffusing capacity for carbon monoxide (55 ±23%predicted). People with ILD had airways that were between 19.6%-45.0% larger than controls (p<0.05). Composite physiologic index, a marker of ILD severity, was not different between sexes (p=0.07). Males with ILD had significantly larger, luminal areas than females in two central airways - right main bronchus (1.46±0.41 vs. 1.07±0.22 mm2/cm, p=0.04) and left upper lobe (0.54±0.10 vs. 0.43±0.08 mm2/cm, p=0.02). However, luminal area of other central airways, including: trachea (2.15±0.57 vs. 1.65±0.32 mm2/cm, p=0.051), bronchus intermediate (0.77±0.23 vs. 0.61±0.13 mm2/cm, p=0.12), right upper lobe (0.47±0.15 vs. 0.40±0.06 mm2/cm, p=0.26), left main bronchus (0.93±0.33 vs. 0.69±0.16 mm2/cm, p=0.09), and left lower lobe (0.41±0.13 vs. 0.40±0.08 mm2 /cm, p=0.79) were not different between sexes in people with ILD. Conclusion: Sex differences observed in healthy people are potentially preserved in ILD, but a more robust sample is required to fully elucidate these findings. Illuminating any sex differences in ILD pathophysiology may provide knowledge to treat and improve clinical outcomes in ILD. Funding: National Heart, Lung, and Blood Institute (F32HL154320 to JWS; 5R35HL139854 to MJJ). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.